Th1 Pathway: The Missing Link Between Inflammatory Bowel Disease and Microscopic Colitis?

Carrasco, Anna; Fernández‐Bañares, Fernando

doi:10.1007/s10620-017-4692-x

Cited by 10 publications

(9 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A few investigators have suggested that microscopic colitis may represent an attenuated form of IBD with transformation to "classical" IBD occurring in a subgroup of patients. [1][2][3] This hypothesis is supported by several lines of evidence. First, the gut microbiome in microscopic colitis is characterized by decreased diversity and marked dysbiosis, 4 similar to that of the gut microbiome in CD and UC.…”

mentioning

confidence: 62%

“…Beyond a number of published case reports and caseseries, 1,8,10 no prior study has systematically examined the relationship between microscopic colitis and risk of incident IBD. Nevertheless, 2 previous studies attempted to examine cases of IBD diagnosed in cohorts of patients with microscopic colitis.…”

Section: Discussionmentioning

confidence: 99%

“…2 Therefore, it has been suggested that microscopic colitis may represent an attenuated form of IBD, with mucosal inflammation largely remaining in check through the anti-inflammatory effect of interleukin-10. 1 However, these compensatory mechanisms may fail in some patients, leading to significant expansion of Th1 and inflammatory Th17 cells and development of classic IBD.…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Microscopic Colitis and Risk of Inflammatory Bowel Disease in a Nationwide Cohort Study

et al. 2020

View full text Add to dashboard Cite

BACKGROUND & AIMS: Microscopic colitis shares pathogenetic mechanisms with inflammatory bowel disease (IBD). We studied the association between microscopic colitis and risk of incident IBD using data from a nationwide cohort study. METHODS: We conducted a prospective cohort study of all adults who received a diagnosis of microscopic colitis from 1990 through 2017 in Sweden and risk of incident IBD. Cases of microscopic colitis (n¼ 13,957) were identified through Systematized Nomenclature of Medicine codes from the ESPRESSO (Epidemiology Strengthened by histoPathology Reports in Sweden) study, which included gastrointestinal pathology reports from all of Sweden's 28 centers. Individuals with microscopic colitis were matched to 5 general population controls (n ¼ 66,820) and to unaffected siblings (n ¼13,943). Cox regression was used to estimate adjusted hazard ratio (aHRs) and 95% confidence intervals (CIs). RESULTS: Through December of 2017, we identified 323 incident cases of ulcerative colitis (UC) and 108 incident cases of Crohn's disease (CD) in patients with microscopic colitis compared with 94 UC and 42 CD cases in population comparators. Mean times from diagnosis of microscopic colitis to diagnosis of CD was 3.3 ± 3.2 years and to diagnosis of UC was 3.2 ± 3.5 years. In multivariable models, microscopic colitis was associated with an aHR of 12.6 (95% CI 8.8-18.1) for CD, 17.3 (95% CI 13.7-21.8) for UC, and 16.8 (95% CI 13.9-20.3) for IBD. The 10-year absolute excess risks of CD and UC were 0.9 (95% CI 0.7-1.1) and 2.6 (95% CI 2.2-2.9) percentage points, respectively. In sensitivity analyses, comparing patients with microscopic colitis with their unaffected siblings, the aHRs of CD and UC were 5.4 (95% CI 3.2-9.2) and 9.4 (95% CI 6.4-13.8), respectively. CONCLU-SIONS: In a population-based study in Sweden, we found a significant increase in risk of incident IBD among patients with microscopic colitis. Future studies should focus on potential mechanisms underlying these observed associations.

show abstract

mentioning

confidence: 62%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Microscopic Colitis and Risk of Inflammatory Bowel Disease in a Nationwide Cohort Study

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Our results indicated that compared with the control group, levels of Th1 (CD4 + /IFN-γ + ) and Th17 cells (CD4 + /IL-17A + ) in the MLN of RTX-treated mice were significantly increased ( Figure 2 ). Th1 cells promote the cell-mediated inflammatory response by inducing the activation of macrophages, NK cells, and B cells ( Carrasco and Fernández-Bañares, 2017 ). Most of the effector capacity of Th17 cells comes from the fact that IL-17, together with TNF-α, strongly promote inflammation by inducing the expression of adhesion molecules, proinflammatory cytokines (e.g., IL-6, GM-CSF, and G-CSF), chemokines, prostaglandin E2 and matrix metalloproteinases ( Kumawat et al, 2013 ; Rauber et al, 2017 ).…”

Section: Resultsmentioning

confidence: 99%

Lactobacillus reuteri Alleviates Gastrointestinal Toxicity of Rituximab by Regulating the Proinflammatory T Cells in vivo

et al. 2021

View full text Add to dashboard Cite

Rituximab (RTX) is a widely used anticancer drug with gastrointestinal side effects, such as nausea, vomiting, and diarrhea. The reason for these side effects is still poorly understood. Previous studies have reported that the intestinal microbiota is associated with the occurrence of disease and the therapeutic effect of drugs. In this study, we observed mucosal damage, inflammatory cell infiltration and increased intestinal inflammatory factor expression in RTX-treated mice. RTX also changed the diversity of the intestinal microbiota in mice, and decreased abundance of Lactobacillus reuteri was observed in RTX-treated mice. Further experiments revealed that intragastric administration of L. reuteri in RTX-treated mice attenuated the intestinal inflammatory response induced by RTX and regulated the proportion of helper T (Th) cells. In conclusion, our data characterize the effect of the intestinal microbiota on RTX-induced intestinal inflammation, suggesting that modifying the gut microbiota may represent a positive strategy for managing adverse reactions.

show abstract

“…Permeability is also increased by non-steroidal anti-inflammatory drugs and proton-pump inhibitors, common MC triggers, that allow antigens to pass into the lamina propria provoking lymphocytosis [2]. Increased expression of TNF-α, interferon-γ, and the Th1-specific transcription factor T-BET in patients with MC who eventually developed IBD suggests a common immunological pathophysiological pathway in the MC-to-IBD transformation [3,10]. Few studies found associations between human leukocyte antigen haplotypes, DQ2 and DQ8, and risk of CC, LC, and IBD development [11][12][13][14][15].…”

Section: Discussionmentioning

confidence: 99%

3155 Macroscopic to Microscopic: A Case of Crohn's Disease Progressing to Collagenous Colitis

et al. 2019

View full text Add to dashboard Cite

The association between microscopic colitis (MC) and inflammatory bowel disease (IBD) is uncertain and infrequently reported. Rare cases in the literature consist of simultaneous MC and IBD, or progression of one condition to the other. We present a unique case of clinically and endoscopically diagnosed and successfully treated IBD that revealed MC on histology months later due to reappearance of diarrhea. Common pathophysiologic mechanisms, such as tumor necrosis factor α and T helper type 1 cells, may explain the MC and IBD relationship. During endoscopy, a prompt biopsy should be taken if suspicious for MC, thus decreasing the duration of patient's symptoms and saving healthcare costs.

show abstract

Th1 Pathway: The Missing Link Between Inflammatory Bowel Disease and Microscopic Colitis?

Cited by 10 publications

References 16 publications

Microscopic Colitis and Risk of Inflammatory Bowel Disease in a Nationwide Cohort Study

Microscopic Colitis and Risk of Inflammatory Bowel Disease in a Nationwide Cohort Study

Lactobacillus reuteri Alleviates Gastrointestinal Toxicity of Rituximab by Regulating the Proinflammatory T Cells in vivo

3155 Macroscopic to Microscopic: A Case of Crohn's Disease Progressing to Collagenous Colitis

Contact Info

Product

Resources

About